Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · IEX Real-Time Price · USD
1.100
-0.040 (-3.51%)
Apr 24, 2024, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for LCTX stock have an average target of 6.50, with a low estimate of 6.00 and a high estimate of 7.00. The average target predicts an increase of 490.91% from the current stock price of 1.10.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 8, 2024.
Analyst Ratings
The average analyst rating for LCTX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +536.36% | Mar 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +536.36% | Feb 13, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $6 | Buy | Reiterates | $6 | +445.45% | Feb 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +536.36% | Aug 11, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $6 | Buy | Reiterates | $6 | +445.45% | Jul 25, 2023 |
Financial Forecast
Revenue This Year
17.83M
from 8.95M
Increased by 99.33%
Revenue Next Year
17.84M
from 17.83M
Increased by 0.06%
EPS This Year
-0.12
from -0.12
EPS Next Year
-0.13
from -0.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 47.3M | 52.5M | 98.4M | 237.6M | 335.7M |
| Avg | 17.8M | 17.8M | 45.1M | 98.4M | 175.9M |
| Low | n/a | 2.5M | 3.3M | 33.2M | 53.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 428.2% | 194.4% | 451.4% | 426.9% | 241.2% |
| Avg | 99.3% | 0.1% | 152.8% | 118.2% | 78.7% |
| Low | - | -85.7% | -81.6% | -26.3% | -45.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.01 | -0.03 | 0.06 | 1.18 | 1.72 |
| Avg | -0.12 | -0.13 | -0.12 | 0.44 | 0.72 |
| Low | -0.22 | -0.23 | -0.20 | -0.02 | 0.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 295.6% |
| Avg | - | - | - | - | 64.8% |
| Low | - | - | - | - | -97.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.